Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
Yi-Qun Che,1 Yue Zhang,1 Di Wang,1 Hui-Ying Liu,2 Di Shen,1 Yang Luo3 1Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Repu...
Saved in:
Main Authors: | Che YQ (Author), Zhang Y (Author), Wang D (Author), Liu HY (Author), Shen D (Author), Luo Y (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
by: Taha Koray Sahin, et al.
Published: (2024) -
LYMPHOPENIA: THE MAIN CAUSES
by: N. T. Vatutin, et al.
Published: (2016) -
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022) -
Impact of baseline lymphopenia on outcomes of definitive treatment for locally advanced cervical cancer
by: Einsley-Marie Janowski, et al.
Published: (2024) -
Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients
by: Elena M. Tosca, et al.
Published: (2023)